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1. SUMMARY 
Background  
Soft tissue tumors, as an important oncology domain, entail different entities and 
are challenging regarding diagnosis and therapy. Here, we focused on synovial sarcoma 
alongside with other soft tissue tumors and specifically analyzed the expression and 
amplification of the gene SOX2 which has the full name SRY (sex determining region 
Y)-box2. SOX2 is a transcription factor responsible for the pluripotency of 
undifferentiated embryonic stem cells, promoting cellular proliferation and promoting 
invasion, migration and metastases in melanoma and other tumors. We also tested  Anti-
Histone H3-trimethyl K27 (H3K27me3) expression in SOX2 positive cases in an 
attempt to correlate SOX2 gene expression with the posttranslational protein 
modification H3K27me3, both of which having been associated with stemness features 
of cancer cells.  
Methodology  
In our study, we included all samples (n=60) of synovial sarcoma at the 
Friedrich-Schiller University hospital of Jena (Germany) between January 2013 and 
December 2015 in a retrospective observational manner. We excluded cases whose 
histopathological material was not available anymore in the institute (n=6) and cases 
(n=4) whose paraffin block was not optimal for further investigation. 
Clinicopathological and Immunohistochemical analysis were performed by our 
institutional pathology team according to standard diagnostic protocols e.g. using 
antibodies against EMA, Bcl2, PanCK, CK7, CD34, Ki67 and S100. Molecular 
confirmation of the diagnosis was routinely performed by FISH and/or PCR to detect 
the t(x;18) translocation. We also employed tissue microarrays of different soft tissue 
tumors to compare the expression in synovial sarcoma with other sarcoma entities. 
Results were collected, tabulated and statistically analyzed.   
Results  
About 60 % of all synovial sarcoma cases were positive to Sox2. Meanwhile out 
of 343 soft tissue tumors, varying from nodular fasciitis to undifferentiated pleomorphic 
sarcoma, only 13 cases (3.8%) were Sox2 positive. Of these, 11 (84.6%) were 
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undifferentiated high grade pleomorphic sarcoma. Out of 35 Sox2 positive synovial 
sarcoma cases, 25 (71, 4%) were H3K27me3 positive and 10 (28, 6%) were negative. 
SOX2 amplification was not detectable in 6 randomly chosen synovial sarcoma cases 
showing SOX2 protein expression.  
Conclusion  
Sox2, a principal stem-cell transcription factor, is evidently involved in the 
tumorigenesis of many tumor entities. In soft tissue tumors, however, expression is 
largely restricted to synovial sarcoma. Immunohistochemical detection of SOX2 can 
thus help in the diagnostic challenge in differentiating synovial sarcoma from other soft 
tissue tumors. H3K27me3 was also found to be positive in the majority of Sox2-positive 
synovial sarcomas and this correlates with the idea that these tumors might have a 
pluripotent cell population as tumor-initiating cells.  We think that this finding supports 
the hypothesis of synovial sarcoma as product of pluripotent mesenchymal stem cell 
populations rather than being derived from mutations in terminally differentiated cells. 
The results may add to the diagnostic scheme for synovial sarcoma diagnosis. 
Moreover, Sox2 might reveal a molecular approach in cancer treatment, namely by 
targeting epigenetic modulators that seems to play a role in SOX2 gene regulation.  
Zusammenfassung 
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Zusammenfassung 
Hintergrund der Studie:  
Weichteiltumoren, eine wichtige onkologische Domäne, setzen sich aus 
unterschiedliche Entitäten zusammen und sind diagnostisch und therapeutisch 
schwierig. Hier konzentrierten wir uns auf das Synovialsarkom, wie auch andere 
Weichteiltumore, und analysierten speziell die Expression und Amplifikation des Gens 
SOX2, das mit vollem Namen SRY (sex determining region Y)-Box2 heisst. SOX2 ist 
ein Stammzell-Transkriptionsfaktor, der für die Pluripotenz undifferenzierter 
embryonaler Stammzellen verantwortlich ist und die Zellproliferation, Invasion, 
Migration und Metastasen bei Melanomen und anderen Tumoren fördert. Daneben 
testeten wir die Anti-Histon-H3-Trimethyl-K27 (H3K27me3)-Expression in den Sox2-
positiven Fällen, um die SOX2 Expression mit der posttranslationalen 
Proteinmodifikation H3K27me3 zu korrelieren, beide Marker wurden mit 
Stamzellcharakteristika von Krebszellen assoziiert. 
Methodik:  
In unserer Studie wurden alle Synovialsarkome (n = 60) zwischen Januar 2013 
und Dezember 2015 an der Friedrich-Schiller-Universitätsklinik in Jena (Deutschland) 
retrospektiv betrachtet. Wir schlossen Fälle aus, deren histopathologisches Material 
nicht mehr im Institut (n = 6) verfügbar oder deren Paraffinblöcke für eine weitere 
Analyse ungenügend waren (n=4). Klinisch-pathologische und immunhistochemische 
Analysen wurden von qualifizierten Mitarbeitern des Institut für Pathologie nach 
Standard-Diagnoseprotokollen etwa unter Verwendung von Antikörpern gegen EMA, 
Bcl2, PanCK, CK7, CD34, Ki67 und S100 durchgeführt. Die molekulare Bestätigung 
der Diagnose erfolgte routinemäßig durch FISH und/oder PCR-Analyse, um die t(x;18) 
Translokation nachzuweisen. Wir haben in dieser Studie auch Gewebe-Microarrays 
verschiedener Weichteiltumoren eingesetzt, um die Expression in Synovialsarkomen 
und anderen Sarkom-Entitäten zu vergleichen. Die Ergebnisse wurden gesammelt, 
tabelliert und statistisch untersucht.  
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Ergebnisse  
Etwa 60% aller Fälle von Synovialsarkomen waren positiv für Sox2. Von 343 
Weichteiltumoren, die von der nodulären Fasziitis bis zu undifferenziertem 
pleomorphem Sarkom reichten, waren nur 13 Fälle (3,8%)  Sox2-positiv. Von diesen 
waren 11 (84,6%) undifferenzierte hochgradige pleomorphe Sarkome. Von 35 Sox2-
positiven Synovialsarkomen waren 25 (71, 4%) H3K27me3-positiv und 10 (28, 6%) 
negativ. Eine SOX2 Amplifikation war nicht nachweisbar in 6 zufällig ausgewählten  
Synovialsarkomen mit SOX2 Expression. 
Schlussfolgerungen  
Sox2, ein Hauptstammzelltranskriptionsfaktor, ist offensichtlich an der 
Tumorigenese vieler Tumorentitäten beteiligt. In Weichtumoren ist die Expression 
jedoch weitgehend beschränkt auf  Synovialsarkome. Der immunhistochemische SOX2 
Nachweis kann damit hilfreich sein in der bisweilen schwierigen 
differenzialdiagnostischen Abgrenzung dieser Entität von  anderen Weichteiltumoren. 
H3K27me3 war ebenfalls nachweisbar in den meisten Sox2-positiven 
Synovialsarkomtumoren und korreliert damit mit der Vorstellung, dass diese Tumoren 
eine pluripotente mesenchymale Stammzell-Population als tumorinitiierende Zellen 
aufweisen könnten. Wir denken, dass dieser Befund die Hypothese stützt, dass das 
Synovialsarkom eher ein Produkt pluripotenter mesenchymaler Stammzellpopulationen 
ist und nicht auf die Mutation terminal differenzierter Zellen zurückgeht. Die 
Ergebnisse könnten das diagnostische Schema für Synovialsarkome bereichern. 
Darüberhinaus könnte sich SOX2 als ein molekularer Ansatz in der Krebstherapie 
entpuppten in dem Sinne einer zielgerichteten Beeinflussung epigenetischer 
Modulatoren, die offenbar bei der Genregulation von SOX2 eine wichtige Rolle spielen. 
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2. INTRODUCTION 
2.1 Stem cells and embryonic stem cells 
Stem cells are characterized by unlimited self-renewal and they also have the 
capacity to differentiate into virtually all tissue types (Takashi et al. 2007; Takashi and 
Yamanaka 2006). Increasing effort is put in the improvement of stem cell 
transplantation therapies to revert the damage that is done by diseases such as 
Alzheimer’s and Parkinson’s diseases. In other closely related fields like spinal cord 
injury, important progress has been made using stem cells to treat patients (Pen et al. 
2016).  
Embryonic stem (ES) cells are pluripotent stem cells derived from the inner cell 
mass of the early stage blastocyst (Yu &Thomson 2008). Self-renewal is crucial to stem 
cell function, because it is required to persist for the life-time of the animal. Moreover, 
whereas stem cells from different organs may vary in their developmental potential, all 
stem cells must self-renew and regulate the relative balance between self-renewal and 
differentiation (Tannishtha et al. 2001). ES cells possess the capacity of unlimited self-
renewal while maintaining pluripotency. Their ability to differentiate into all cell types 
of the three embryonic germ layers makes them interesting candidates for cell 
replacement therapies and has led to the identification of three core transcription factors 
that are essential for maintenance of ES cells: Oct4, Sox2 and Nanog (Chen & Daley 
2008). Many stem cell-specific transcription factors, including the pluripotency 
transcription factors, Oct4, Nanog and Sox2 function in combinatorial complexes to 
regulate the expression of loci, which are involved in embryonic stem (ES) cell 
pluripotency and cellular differentiation (Kashyap et al. 2009). 
Considerable effort has also been invested in attempts to dedifferentiate somatic 
cells towards pluripotency, a strategy that could be used for personalized regenerative 
medicine. One approach is to virally induce exogenous expression of transcription 
factors forming induced pluripotent stem cells (Johansson et al. 2010). 
As well as the experimental induction of pluripotency is done by somatic cell 
nuclear transfer (Byrne et al. 2007), nuclear programming/cell fusion experiments (Lluis 
Introduction 
 
 
6 
et al. 2008), and most recently by retroviral introduction of the four critical genes, now 
sometimes referred to as Yamanaka factors: Oct4, Sox2, Klf4 and c-Myc or a 
combination of Oct4, Sox2, Nanog and Lin28 (Yu et al. 2007). This technique has 
permitted the reprogramming of multiple distinct mouse and human differentiated cell 
types to yield induced pluripotent stem (iPS) cells (Yamanaka et al. 2008). These iPS 
cells are similar to embryonic stem (ES) cells in morphology, proliferation and capacity 
to form teratomas (Takahashi et al. 2006). 
 
Fig 1: Pluripotent stem cells can be derived from cells isolated from the inner cell mass of early stage 
blastocysts (A) or experimentally derived by epigenetic reprogramming of differentiated adult cell types 
(B). Greatest reprogramming efficiency is achieved when combinations of 4 factors, OCT4, SOX2, c-
MYC, and KLF4, or OCT4, SOX2, NANOG, and LIN28 genes are introduced into the differentiated cell. 
However, OCT4 and SOX2 appear critically required to induce pluripotency (Kashyap et al. 2009). 
 
The highest efficiencies of induced pluripotency are achieved when all four 
factors (Yamanaka factors) were utilized; however c-Myc and Klf4 have been shown to 
be dispensable for somatic cell reprogramming to pluripotency under specific culture 
conditions (Nakagawa et al. 2008). Specifically, the histone deacetylase inhibitor 
valproic acid (VPA) both enhances the efficiency of iPS derivation by the combined 
four factors and permits the derivation of iPS cells using just Oct4 and Sox2 (Huangfu 
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et al. 2008). These studies indicate that Oct4 and Sox2 are critical factors required for 
maintaining self-renewal and pluripotency of mouse and human stem cells (Guo G et al. 
2009). 
Two major studies have demonstrated that Oct4, Nanog and Sox2 share a 
substantial fraction of target genes and in fact, co-occupy genes in both mouse and 
human ES cells (Boyer et al. 2005). As reported by Boyer and colleagues, these genes 
occupy collectively about 10 % of the promoters in the human genome. About half of 
the promoter regions bound by Oct4 were also bound by Sox2 and 90% of these doubly 
bound genes were in turn bound by Nanog (Boyer et al. 2008). Moreover, the OCT4, 
SOX2 and NANOG-binding sites were in close proximity, further confirming that the 
proteins work in concert (Loh et al. 2006). 
Oct4, Nanog, Sox2 and a number of associated transcription factor proteins 
activate and maintain the expression of genes involved in self-renewal, while 
simultaneously repressing genes that mediate differentiation (Wu et al. 2006). Thus 
Oct4, Nanog and Sox2 form a self-reinforcing and intricately connected network that 
preserves ES cell character (Yang et al. 2008). 
2.2 Induced pluripotent stem cells and the Yamanaka Factors 
In 2006, Shinya Yamanaka was the first to successfully reprogram cells using 
four distinct factors, thereby generating induced pluripotent stem cells (iPSCs) from 
terminally differentiated fibroblasts. IPSCs can be established by the over expression of 
four key transcription factors: Oct4, Klf4, Sox2 and c-Myc (OSKM) (Takashi et al. 
2007; Takashi and Yamanaka 2006). One of the major advantages of iPSCs is that they 
can be made autologous and can provide a sufficient quantity of cells by culturing, 
making the use of other stem cell sources unnecessary (Pen et al. 2016).  
Reprogramming of any somatic cell type can be achieved by initiating several 
synergistic processes. In the process of reprogramming, induced pluripotency elicits 
several transcription waves driven by c-Myc/Klf4 and Oct4/Sox2/Klf4. The expression 
levels of distinct pluripotency genes (alkaline phosphatase (AP), stage specific 
embryonic antigen (SSEA), Nanog and Oct4) increase step wise (Brambrink et al. 
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2008), and upon achieving stable pluripotency levels, their DNA methylation patterns 
are changed (Polo et al. 2012). Nonetheless, the exact mechanisms of reprogramming 
still remain unclear. Obviously the reprogramming factors reactivate an endogenous 
pluripotency circuitry by re-inducing the cells’ capacity for unlimited growth without 
inducing genetic alterations, as it is frequently observed in cancer (Polo et al. 2012). 
It has been demonstrated that abbreviated reprogramming factor expression 
pattern results in dysplasia and tumor formation in vivo, thus suggesting that OKSM has 
an impact on epigenetic changes that are substantially involved in the regulation of cell 
growth and tumorigenesis (Ohnishi et al. 2014). This observation is corroborated by the 
fact that iPSCs form teratomas upon implantation in vivo (Magnuson et al. 1982). Of 
note, human iPSCs develop teratomas more efficiently and faster than human 
embryonic stem cells (Gutierrez-Aranda et al.2010; Avior et al. 2015). 
 
Fig 2: In vivo overexpression of the four pluripotency factors OCT4, c-MYC, KLF4 and SOX2 (OSKM) 
leads to epigenetic changes resulting in dysplasia. Extension of OSKM overexpression subsequently 
drives tumor formation. Both dysplasia and tumor formation result from an incomplete reprogramming 
process. Cells derived from these tumors can be fully reprogrammed towards unaltered iPSCs that do not 
have tendencies to re-initiate tumorigenesis after blastocyst injection. In case of complete in vivo 
reprogramming, teratoma formation becomes apparent. Figure is adapted from Ohnishi et al. (2014). 
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Several studies have assigned the OKSM factors to tumorigenesis. Abad et al. 
were the first to successfully reprogram in vivo by transiently inducing OSKM, 
resulting in teratomas formation, and detection of fully reprogrammed cells in various 
tissue types. The presence of the niche in vivo even allowed superior reprogramming to 
the totipotent state (Abad et al. 2013). Intriguingly, further studies showed that partial or 
incomplete reprogramming induced particular tumor types in vivo (Ohnishi et al. 2014). 
More importantly, up regulation of these proteins was associated closely with 
tumor metastases and poor prognosis in various human malignancies including prostate 
cancer, lung adenocarcinoma, gliomas, rectal cancer, gastric carcinoma and oral 
squamous cell carcinoma (Chiou et al. 2010; Guo et al. 2011; Matsuoka et al. 2012). 
The mesenchymal phenotypic changes by increased motility and invasiveness of 
epithelial tumor cells are known as epithelial-mesenchymal transition (EMT). EMT is 
defined by the loss of epithelial morphology and the acquisition of a mesenchymal 
phenotype, which is initially found to be a central program in early embryonic 
morphogenesis (Lim et al. 2012). 
 In a few years, evidence has mounted for EMT as the key means through which 
cancer cells acquire more highly mobile potentials to migrate and metastasize to distant 
sites during tumor progression (Scheel and Weinberg 2011). E-cadherin, a classical 
cadherin from the cadherin superfamily, is required for maintaining epithelial cell 
plasticity. N-cadherin, known as an important member of the cadherin family that 
mediates calcium-dependent adhesion, is normally expressed in mesenchymal cells. 
Loss of E-cadherin and increased N-cadherin expression (E/N cadherin switch) is now 
defined as a major hallmark of EMT (Nakajima et al. 2004; Werling et al. 2011).  
Over the past few years, accumulating data has demonstrated that EMT 
correlates closely with the acquisition of stem cells-like properties in cancer cells 
(Polyak et al. 2009; Sarkar et al. 2012). 
Luo et al. showed that overexpression of Sox2, Oct4 and Nanog were 
significantly associated with high expression of N-cadherin, but adversely with low E-
cadherin expression (except SOX2). Additionally, overexpression of these proteins 
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correlated strongly with the expression of Snail, a central transcription factor as E-
cadherin repressor (Luo et al. 2013). 
In the kidney, OKSM-induced tumors bear features of a Wilm’s tumor, a 
common pediatric cancer. Interestingly, these tumors only display epigenetic alterations, 
as indicated by global changes in their DNA methylation patterns (Müller et al. 2016). 
Interestingly, reprogramming of OKSM-induced tumors resulted in non-
tumorigenic iPSCs that contributed to regular organ formation upon subsequent 
differentiation in vivo. This indicates that reprogramming with the Yamanaka factors 
primarily leads to epigenetic alterations, generating a “cancer-poised” but not yet 
“cancer-committed” state (Ohnishi et al. 2014). 
2.3 Cancer and cancer stem cells 
Similar to normal tissues, cancer compromise heterogeneous cell populations 
with distinct phenotypes, functions and gene expression profiles (Marte 2013). The 
phenotypic characteristics of some cancer cells, particularly of poorly differentiated to 
undifferentiated tumors have been found to be quite similar to undifferentiated 
embryonic cells (Curry et al. 2015). 
 A tumor can be viewed as an aberrant organ initiated by a tumorigenic cancer 
cell that acquired the capacity for indefinite proliferation through accumulated 
mutations (Reya et al. 2001). If one views a tumor as an abnormal organ, then the 
principles of normal stem cell biology can be applied to understand better how tumors 
develop (Kummermehr 2001). Both normal stem cells and tumorigenic cells have 
extensive proliferative potential and the ability to give rise to new (normal and 
abnormal) tissues. Both tumors and normal tissues are composed of heterogeneous 
combinations of cells, with different phenotypic characteristics and different 
proliferative potentials (Nowell 1986). 
Because most tumors have a clonal origin (Fearon et al. 1987), tumorigenic 
cancer cells must give rise to phenotypically diverse progeny, including cancer cells 
with indefinite proliferative potential, as well as cancer cells with limited or no 
proliferative potential. This suggests that tumorigenic cancer cells undergo processes 
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that are analogous to the self-renewal and differentiation of normal stem cells (Reya et 
al. 2001). 
Both normal stem cells and tumorigenic cells give rise to phenotypically 
heterogeneous cells that exhibit various degrees of differentiation. Thus, tumorigenic 
cells can be thought of as cancer stem cells that undergo an aberrant and poorly 
regulated process of organogenesis analogous to what normal stem cells do (Sell et al. 
1994) 
The cancer stem cell (CSC) hypothesis posits that tumors may be initiated and 
maintained by a subset of cells that maintain or acquire stem-cell properties and that 
each tumor contains a small subpopulation of cells that have the ability to differentiate 
into multiple cell lineages and self-renew (Jordan et al. 2006; Reya et al. 2001). Cancer 
stem cells or cancer stem-like cells have been identified in several solid tumor types 
such as breast cancer and colon cancer (Al-Hajj et al. 2003) This subpopulation is 
closely associated not only with carcinogenesis, but also with recurrence and metastasis 
of tumors (Jordan CT et al. 2006). 
Small numbers of stem cells are believed to exist in most if not all adult tissues 
(Blanpain et al. 2009). Adult stem cells can evade the stringent genetic controls of their 
normal pathways of cellular differentiation and proliferation and give rise to cancer. 
Cancer stem/initiating cells have been defined as a subset of cancer cells that have the 
exclusive ability of self-renewal and cause the heterogeneous lineages of cancer cells 
that comprise the tumor (Hill et al. 2007). 
These cancer stem cells are implicated in cancer initiation, malignant potential, 
metastatic progression, and in the post treatment recurrence of many human cancer 
types (Dalerba et al. 2008). Stem cell-specific proteins, including Oct4, Nanog and 
Zfp42/Rex1 are implicated in some cancers (Chiou et al. 2008). Histologically poorly 
differentiated tumors showed preferential overexpression of genes normally enriched in 
ES cells. Activation targets of Nanog, Oct4, Sox2 and c-Myc are more frequently 
overexpressed in poorly differentiated tumors than in well-differentiated tumors (Ben-
Porath et al. 2008). It appears that the genes active in both ES cells and cancer stem 
cells are controlled by a few master regulatory genes (Wong et al. 2008) 
Introduction 
 
 
12 
2.4 Sox2 
SRY(sex determining region Y)-box2, also known as Sox2, is a transcription 
factor that is essential for maintaining self-renewal or pluripotency of undifferentiated 
embryonic stem cells and plays a critical role in maintenance of embryonic and neural 
stem cells (Rizzino 2009). The Sox2 gene is located on chromosome 3q26.3-q27, 
belongs to the SoxB1 group and encodes for a protein consisting of 317 amino acids 
(Collignon et al. 1996). Sox2 research thus far has heavily emphasized its crucial role in 
stem cell maintenance, lineage fate determinant and as a necessary factor to reprogram 
somatic cells back towards pluripotency (Takahshi and Yamanaka 2006). 
Varying levels of SOX2 affect embryonic stem cells’ fate of differentiation. 
SOX2 inhibits differentiation into mesoderm germ layer and promotes differentiation 
into neural ectoderm germ layer (Thomson et al. 2011). A study conducted in Milano, 
Italy showed, through the development of a knockout model, that deficiency of SOX2 
results in neural malformations and eventually fetal death, further underlying SOX2’s 
vital role in embryonic development (Ferri et al. 2004). 
In addition to its fundamental role in the maintenance of embryonic stem cells, 
SOX2 is important during embryonic development of gastrointestinal organs: it is 
expressed in the developing foregut and gastric epithelium. SOX2 co-localizes with p63 
in the basal layer of the esophagus and is critical in the maintenance of the stratified 
squamous epithelium; however it is down regulated in intestinal metaplasia of the 
stomach and esophagus (Long and Hornick. 2009). 
In neurogenesis, SOX2 is expressed throughout developing cells in the neural 
tube as well as in proliferating central nervous system progenitors (Graham et al. 2003). 
Cells expressing SOX2 are capable of both producing cells identical to themselves and 
differentiated neural cell types, two necessary hallmarks of stem cells (Suh et al. 2007). 
In diseases, SOX2 alterations have been associated with developmental 
maladies, such as anophthalmia-esophageal-genital (AEG) syndrome which occurs 
when there is a heterozygous mutation of Sox2 that leads to abnormal development of 
ectodermal and endodermal tissues (Williamson et al. 2006).  
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Cancer is a disease characterized by determined hallmarks, some of which are: 
sustained proliferative signaling, activation of invasion and metastases, and evasion of 
cell death (Hanahan and Weinberg, 2011). The orchestration of tumor initiation and 
maintenance has been shown in some cancers to be driven by cancer stem cells (CSCs). 
These cells may acquire tumor-initiating and self-renewal properties through similar 
molecular mechanisms governing cellular reprogramming (Vazquez-Martin et al. 2013). 
Sussman and colleagues discovered that the ubiquitin-specific protease 22 
(USP22) is responsible for controlling the cellular transition from stemness towards 
differentiation (Sussman et al. 2013). Moreover they found USP22 represses the SOX2 
promoter in order to control the embryonic stem cell transition from self-renewal to 
differentiation (Sussman et al. 2013). Therefore, not only is Sox2 an essential stem cell 
marker but its suppression is mandatory for cellular differentiation. For these reasons, 
Sox2 has been heavily investigated in CSCs in several cancer types (Weina and Utikal 
2014) 
SOX2 amplification has been found in several cancer types including 
glioblastoma, small-cell lung cancer (SCLC) and many forms of squamous cell 
carcinoma (SCC) (Rudin et al. 2012). 
SOX2 has been shown to promote cellular proliferation in breast, prostate, 
pancreatic and cervical cancers (Herreros-Villanueva et al. 2013), evade apoptotic 
signals in prostate, gastric cancer and non-small cell lung carcinoma (Herreros-
Villanueva et al. 2013; Chen et al. 2013) and promote invasion, migration and 
metastases in melanoma, colorectal glioma, gastric, ovarian cancer and hepatocellular 
carcinoma (Sun et al. 2013; Lou et al. 2013). 
Cellular proliferation is tightly regulated by Sox2 in many cancer types. Sox2 
knockdown in pancreatic cancer cells resulted in cell growth inhibition through cell 
cycle arrest, not apoptosis (Herreros-Villanueva et al. 2013). When Sox2 was over 
expressed, cell proliferation was promoted through cyclinD3 (Herreros-Villanueva et al. 
2013). 
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Additionally, Fang and colleagues found in lung small cell carcinoma (LSCC), 
SOX2-silencing inhibited cellular proliferation via the up regulation of BMP4 (Fang et 
al. 2014). After performing chromatin immunoprecipitation and luciferase experiments, 
SOX2 was found to transcriptionally repress the BMP4 promoter. The authors therefore 
suggest that BMP4 is playing a tumor suppressor role in LSCC, while SOX2 repression 
of BMP4 transcription causes cell growth (Fang et al. 2014). It’s also important to note 
that the involvement of SOX2 in cell proliferation has been controversially discussed in 
colorectal and gastric cancer (Liu H et al. 2013). 
SOX2 also plays an important role in evading apoptotic signals. In prostate 
cancer, in vitro and in vivo xenograft experiments using DU145 Sox2-overexpressing 
cells in NOD/SCID mice revealed that SOX2 caused an increase in apoptotic resistance 
by decreasing store-operated calcium entry (Jia et al. 2011). Equivalently, upon 
silencing of SOX2 in non-small cell lung carcinoma (NSCLC) cell lines, apoptosis was 
induced (Chen et al. 2013) 
Research has indicated that SOX2 is a novel regulator of cell invasion, migration 
and metastasis. For example, in melanoma, SOX2 knockdown in A2058 cells resulted 
in a 4.5 fold decrease in invasion in vitro (Girouard et al. 2012). Likewise in colorectal 
cells, SOX2 was involved in cellular migration and invasion in vitro (Han et al. 2012). 
This invasive phenotype was also confirmed in malignant glioma, since siRNA-
mediated down regulation of SOX2 resulted in a significant decrease in migration and 
invasion capabilities (Alonso et al. 2011). 
2.5 Soft Tissue Tumors 
2.5.1 Epidemiology  
The incidence of soft tissue tumors, especially the frequency of benign tumors 
relative to malignant ones, is nearly impossible to determine accurately. Benign soft 
tissue tumors outnumber malignant tumors by a wide margin (Goldblum et al. 2014). 
However, according to an analysis of the Surveillance, Epidemiology and End Results 
(SEER) database, the incidence changes with age; for children younger than 10 years of 
age, the annual incidence was 0.9/100,000 in children but rose to 18.2/100,000 in adults 
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over the age of 70 years. The most dramatic increases occurred at 30 and 70 years of 
age (Ferrari et al. 2011). 
Soft tissue sarcomas are rare tumors, representing less than one percent of all malignant 
neoplasms (Katenkamp and Katenkamp 2009). Adult soft tissue tumors are not 
represented in the figures of the Robert Koch Institute reporting of 427 000 individuals 
in Germany being diagnosed with cancer in 2006 (Bertz et al. 2010). Assuming that 
mesenchymal malignancies constitute about one-hundredth of all cancer diagnoses 
(Fletcher et al. 2006), an estimated number of 4500 Germans annually develop a 
sarcoma.  
2.5.2 Classification 
Soft tissue tumors constitute a large and heterogeneous group of neoplasms 
(Fletcher et al. 2006). Traditionally, soft tissue sarcomas have been classified according 
to a histogenetic concept (e.g., fibrosarcoma as a tumor arising from fibroblasts, 
osteosarcoma as a tumor arising from osteoblasts, and so on). However morphologic, 
immunohistochemical and data from experimental animals suggest that most if not all 
sarcomas arise from primitive multipotential mesenchymal cells, which in the course of 
neoplastic transformation undergo differentiation in one or more lines (Mills et al. 
1995).  
The acceptance of this alternative scheme does not require a change in 
terminology: a liposarcoma remains as such but is now viewed not as a tumor arising 
from a lipoblast but as a tumor exhibiting lipoblastic differentiation (Fletcher et al. 
2006). 
2.5.3 Pathogenesis 
The large majority of soft tissue sarcomas arise de novo rather than from 
malignant degeneration of preexisting benign tumors. Although the latter phenomenon 
may occur (as in neurofibromas), in most cases in which a given benign tumor is said to 
have become malignant, review of the original material showed that it was malignant 
from its inception (Laskin et al. 1988).  
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2.5.4 Environmental factors  
Trauma is frequently implicated in the development of sarcomas. Much has been 
written in the medical and legal literature on the possible relationship between trauma 
and soft tissue sarcoma, but no convincing evidence has been provided for a definite 
cause-effect relationship between the two (Monkman et al.1974). Rare soft tissue 
sarcomas have been reported as arising in scar tissue following surgical procedures or 
thermal or acid burns, at fracture sites, and in the vicinity of plastic or metal implants, 
usually after a latent period of several years (Piscitelli et al. 2011). 
Worth noting is that trauma, whether etiologically related to a tumor or proven 
to be indulged in tumor-emergence by causing specific genetic alterations, should be 
regarded as more than just a random co-incidence. The emergence of mutations, for 
example, may be favored in the proliferative state that occurs within fibroblasts in the 
setting of a trauma (Petersen 2017). 
Phenoxyacetic acid herbicides, chlorophenols and their contaminants such as 2, 
3, 7, 8-tetrachlorodibenzo-para-dioxin (dioxin) have been linked to sarcomagenesis 
(Zambon et al. 2007; Collins et al. 2009). A series of case-control studies from Sweden 
from 1979 to 1990 reported an up to six fold increased risk of soft tissue sarcoma 
associated with exposure to phenoxyacetic acids or chlorophenols in individuals 
exposed to these herbicides in agricultural or forestry work (Hardell et al. 1998). Similar 
reports of an increased risk of sarcoma associated with these herbicides were reported 
from Italy (Bertazzi et al. 2001), Great Britain and New Zealand. 
The possibility of an increased incidence of sarcomas was claimed for some of 
the two million soldiers stationed in Vietnam between 1965 and 1970 who were 
exposed to Agent Orange, a defoliant that contained dioxin as a contaminant 
(Kramárová et al. 1998). Vinyl chloride exposure is clearly associated with the 
development of hepatic angiosarcoma (Sahmel et al. 2009; Sherman M et al. 2009).  
Radiation exposure has been related to the development of sarcomas, but 
considering the frequency of radiotherapy, radiation-induced soft tissue sarcomas are 
quite uncommon. The incidence of post-radiation sarcoma is difficult to estimate, but 
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reports generally range from 0.03% to 0.8% (Mark et al. 1996; Inoue et al. 2000). 
Nearly all post-radiation sarcomas occur in adults, and women develop these tumors 
more frequently, an observation which reflects the common use of radiation for the 
treatment of breast and gynecologic malignancies (Weaver et al. 2009).  
Although the incidence of radiation associated angiosarcoma (RAAS) is low, the 
number of cases reported is increasing as a function of the improved likelihood of 
surviving early stage breast carcinoma. Furthermore, with increased use of external 
beam radiation in the management of breast cancer patients, the incidence of post-
radiation sarcomas may increase in the future. Long-term follow-up is needed for early 
disease detection (Torres et al. 2013). 
Unfortunately most post radiation sarcomas are high-grade lesions and are 
detected at a relatively higher stage than their sporadic counterparts (Billings et al. 
2004). Patients with radiation-induced sarcoma of the extremities have the best survival 
(approximately 30% at 5 years), whereas those with lesions arising in the vertebral 
column, pelvis and shoulder girdle generally have survival rates of less than 5% at 5 
years (Fang et al. 2004). 
2.5.5 Oncogenic Viruses 
The role of oncogenic viruses in the evolution of soft tissue sarcomas is still 
poorly understood, although there is strong evidence that the human herpesvirus 8 
(HV8) is the causative agent of Kaposi’s sarcoma (Mesri et al. 2010). In addition, there 
is a large body of literature supporting the role of the Epstein-Barr virus in the 
pathogenesis of smooth muscle tumors in patients with immunodeficiency syndrome or 
following therapeutic immunosuppression in the transplant setting (Deyrup et al. 2006).   
2.5.6 Immunologic factors 
Acquired immunodeficiency, or loss of immune surveillance, may lay a central 
role in the development of the relatively rare angiosarcomas that arise in the setting of 
chronic lymphedema (Shon et al. 2011), secondary to radical mastectomy (Stewart-
Treves syndrome) (Dawlatly et al. 2011) or congenital or infectious conditions (Roy et 
al. 2004). 
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2.5.7 Genetic factors 
A number of genetic diseases are associated with the development of soft tissue 
tumors, and the list will undoubtedly lengthen as we begin to understand the molecular 
underpinnings of mesenchymal neoplasia. Neurofibromatosis type 1, neurofibromatosis 
type 2 and familial adenomatous polyposis (FAP)/Gardner syndrome are classic 
examples of genetic diseases associated with soft tissue tumors (Goldblum et al. 2014) 
2.5.8 Clinical Features 
A definite relationship exists between soft tissue tumor type and the age of 
presentation (Rydholm et al. 1984). For instance, embryonal rhabdomyosarcoma is 
typically a tumor of infants and children, synovial sarcoma typically affects adolescents 
and young adults, liposarcomas and undifferentiated pleomorphic sarcomas are usually 
seen in middle-aged and elderly patients. It is interesting that congenital soft tissue 
tumors rarely behave in a malignant fashion (Kauffman et al. 1965). 
Most soft tissue sarcomas are solitary. Synchronous or metachronous multiple 
sarcomas represent only 0.2% of all cases. Liposarcomas account for a high percentage 
of these cases (Grobmyer et al. 2004). 
2.5.9 Diagnosis  
Appropriate diagnoses are of great importance to the patient to obtain the 
adequate therapy. Since misdiagnoses are not uncommon, specialist centers provide 
valuable resources for the verification of suspected malignant mesenchymal tumors 
(Lehnhardt et al. 2009; Petersen et al. 2011). 
For any large soft tissue tumor in which the possibility of malignancy exists, the 
proper initial diagnostic procedure is to obtain material through incisional biopsy or fine 
needle aspiration. The latter technique is being used with increased frequency in the 
United States, with rates of accuracy equivalent to those obtainable with frozen section 
(Layfield et al. 1986). 
Light microscopic evaluation of hematoxylin-eosin-stained sections remains the 
standard technique for the initial diagnostic approach to these tumors and is sufficient in 
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the majority of the cases (Enjoji et al. 1984). However, there are special techniques that 
have been successfully applied to increase diagnostic accuracy and which sometimes 
are indispensable, this development applying both to adult and pediatric tumors 
(Iwasaki et al. 2009). These techniques include conventional special stains, electron 
microscopy, immunohistochemistry and molecular genetic methods (Rosai and 
Ackerman 2011). 
Immunohistochemistry for tissue-related markers has proved to be of great value 
and is now extensively used to accurately classify these neoplasms: the specificity, 
sensitivity and applicability of this technique to routinely processed material clearly 
render it the method of choice in most circumstances (Heim-Hall et al. 2008). The 
number of available markers is very large and continues to grow (Ordóñez et al. 1998). 
The systemic use of cytogenetics has shown the existence of nonrandom 
chromosomal alterations (mainly translocations) in association with many types of soft 
tissue tumor (Sandberg AA et al. 2002). 
Gene fusions have been described in approximately one-third of soft tissue 
tumors (STT); of the 142 different fusions that have been reported, more than half are 
recurrent in the same histologic subtype. These gene fusions constitute pivotal driver 
mutations, and detailed studies of their cellular effects have provided important 
knowledge about pathogenetic mechanisms in STT (Mertens et al. 2016). 
The findings have validated the morphologic approach to classification of soft 
tissue tumors, helped to refine the boundaries of some entities and offered insight into 
the genesis of the tumors. Furthermore, the molecular alterations (gene fusions) that 
result from the chromosomal translocations can now be readily demonstrated in routine 
paraffin-embedded tissues by reverse transcriptase polymerase chain reaction (RT-PCR) 
or fluorescent in situ hybridization (FISH), and such studies can be extremely helpful in 
the diagnosis of these tumors especially in small biopsies, tumors with unusual 
morphology, or tumors in unusual sites (Antonescu et al. 2006).  
As an example, a break-apart FISH probe against the EWS (also known as 
EWSR1) gene is particularly helpful since this gene is implicated in many different soft 
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tissue tumor types, including Ewing sarcoma/PNET, angiomatoid fibrous histiocytoma, 
extraskeletal myxoid chondrosarcoma, myxoid liposarcoma, clear cell sarcoma of 
tendons and aponeurosis and desmoplastic small cell tumor (Chang et al. 2003).  
2.5.10 Grading and Staging 
Some degree of microscopic grading of soft tissue is already built into the 
conventional microscopic classification of these tumors. The number of grades has 
varied in the different systems: two (low-grade and high-grade), three (I, II and III or 
low-grade, intermediate-grade and high-grade) and four (I, II, III and IV) grades have 
been recognized (Deyrup et al. 2006).  
The criteria used have included degree of cellularity, pleomorphism, mitotic 
activity and necrosis and have been found to be of definite prognostic value for both 
adult and pediatric soft tissue tumors (Coindre et al. 1988), however it is misleading to 
over-emphasize grading that is independent of the specific microscopic type of the 
sarcoma and the circumstances in which it occurs, such as the patient’s age or the depth 
and size of the tumor (Deyrup et al. 2006). 
The two grading schemes that have been most widely applied are those of the 
French Federation of Cancer Centers Sarcoma Groups and the National Cancer Institute 
(Coindre et al. 2001). The WHO meanwhile propagates the “Fédération Nationale des 
Centres de Lutte Contre le Cancer”; FNCLCC system (Fletcher et al. 2013) 
French federation of Cancer Centers Sarcoma Group (Fédération 
Nationale des Centres de Lutte Contre le Cancer”; FNCLCC system) grading system 
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Tumor Differentiation 
Score 1 
Sarcomas closely resembling normal adult mesenchymal tissue. 
Examples: well-differentiated liposarcomas and well-differentiated 
fibrosarcoma. 
Score 2 
Sarcomas for which the histologic typing is certain. Examples: 
biphasic synovial sarcoma, alveolar soft-part sarcoma, myxoid 
liposarcoma 
Score 3 
Embryonal sarcomas, undifferentiated sarcomas and sarcomas of 
doubtful tumor type 
Mitosis count 
Score 1 0-9 mitoses per 10 high power fields 
Score 2 10-19 mitoses per 10 high power fields 
Score 3 More than 20 mitoses per 10 high power fields 
Tumor necrosis 
Score 0 No necrosis on any examined slides 
Score 1 Less than 50% tumor necrosis for all the examined tumor surface 
Score 2 Tumor necrosis on more than half of the examined tumor surface 
 
The three grade system is set-up as follows: Grade I is defined as a total of 2 or 3 
when summing the scores obtained for each of the three histologic criteria; grade II 
represents a total of 4 or 5; grade III represents a total of 6, 7 or 8. 
Two main staging systems for soft tissue sarcoma have been proposed. The one 
exposed by the American Joint Committee (AJC) is largely based on the TNM system, 
in that it uses the size of the primary tumor (T), the status of lymph nodes (N), the 
presence of distant metastases (M), and the tumor’s histological grade (G) (Behars et al. 
1992). 
2.5.11 Prognosis 
Prognosis of soft tissue tumors depends on a variety of parameters, many of 
which are interrelated. 
 Tumor size: there is a definite relationship between tumor size and outcome. This is 
true for practically all tumor types in which this parameter has been analyzed 
(Rooser et al. 1988). 
 Depth: Superficially located tumors (dermis and subcutaneous tissue) have a much 
better prognosis than deep-seated ones (intermuscular or intramuscular, 
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retroperitoneal) of similar microscopic type (Gerrand et al. 2003). Along similar 
lines, soft tissue sarcomas featuring histologic evidence of bone invasion have a 
poorer prognosis (Ferguson et al. 2006). 
 Location: Tumors of the retroperitoneum do much worse than microscopically 
similar lesions located in the extremities. Among the latter, local recurrence has 
been found to be more frequent with sarcomas of the upper extremity than those of 
the lower extremity (Gerrand et al. 2003). 
 Microscopic type: Some soft tissue neoplasms (such as atypical lipomatous tumors) 
are low-grade lesions with no capacity to metastasize, whereas other neoplasms of 
similar cell type (such as pleomorphic liposarcoma) are highly aggressive and prone 
to spread distantly (Rosai and Ackerman 2011). 
 Vascular invasion: This has been shown to be the strongest predictor of distant 
metastases in several series (Engellau et al. 2005). 
 Surgical margins: Not surprisingly, adequacy of surgical margins is statistically 
associated with low relapse (Stojadinovic et al. 2002). 
 Microscopic grade: A relationship has been found between various microscopic 
grading systems and outcome, which in some cases is directly related to the 
histotype but in others it is applied within a given histotype (Rosai and Ackerman 
2011). 
 Clinical stage: this determination, which incorporates several of the previously 
mentioned parameters, as well as the presence or absence of metastases, is the most 
powerful prognostic determinator (Rosai J and Ackerman LV. 2011). 
 DNA ploidy: Several flow cytometric studies performed in soft tissue sarcomas of 
various microscopic types have shown that DNA ploidy correlates with a higher 
microscopic grade, a higher rate of cell proliferation and decreased survival rates 
(Kroese MC et al. 1990). 
 Cell proliferation: Mitotic activity is incorporated in most grading schemes. 
Evaluation of proliferation markers such as MIB-1 and p105 has been shown to 
correlate with prognosis (Hasegawa et al. 2007) 
 Genetic alterations: It has been shown that soft tissue tumors exhibiting mutations of 
TP53 or altered expression of retinoblastoma gene behave more aggressively than 
those lacking these changes (Kawai A et al. 1994). Claims have been made of a 
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relationship between the type of gene fusion in the sarcomas associated with 
chromosomal translocations and prognosis (as in alveolar rhabdomyosarcoma and 
synovial sarcoma) (Rosai and Ackerman 2011). 
2.6 Synovial Sarcoma 
Synovial sarcoma is a rare and aggressive soft tissue tumor that accounts for 
approximately 10% of soft tissue sarcomas and classically occurs in the extremities of 
young adults (Amary et al. 2007; Terry et al. 2007). It occurs at any age but the peak 
incidence is between the ages of 10 and 35 years; with a slight male predominance. The 
anatomic distribution is wide, but more than 60% arise in the lower limb (Bergh et al. 
1999). A small but significant proportion of cases arise on the trunk, especially in the 
abdominal wall (Fetsch et al. 1993) in the neck (Roth et al. 1975), in the head 
(Shmookler et al. 1982), in the mediastinum (Suster et al. 2005) and even in the 
abdominal cavity (Fisher et al. 2004). 
Overall 5-year survival probability is about 60-65% but falls to only around 30% 
at 10 years. In general, small tumor size (<5 cm), early clinical stage, early age at 
presentation (<10 years) and lower histologic grade (as defined by mitotic activity and 
necrosis) are signs of a better prognosis (Lewis et al, 2000). 
Synovial sarcoma falls into two main groups, monophasic composed entirely of 
spindle cells and biphasic showing both epithelial and spindle cell components. The 
monophasic variant is more common, depending on sampling (Fletcher et al. 2002). 
Approximately 5-10% of cases have a poorly differentiated appearance, most often 
characterized by undifferentiated round cell morphology. These appear to be relatively 
more frequent in elderly patients with synovial sarcoma (Chan et al. 2003). 
Immunohistochemically, in addition to positive staining in the obviously 
epithelial component, in almost all cases the spindle cell element also shows at least 
focal positivity for epithelial membrane antigen (EMA) and keratin; this, combined with 
morphologic clues, is generally the best way to distinguish monophasic lesions from 
malignant peripheral nerve sheath tumor (MPNST) or fibrosarcoma (Pelmus M et al. 
Introduction 
 
 
24 
2002). Around 30% of cases of synovial sarcoma are S-100 protein positive, similarly at 
least two thirds of synovial sarcomas stain positively for CD99 (Pelmus et al. 2002). 
Cytogenetically, both biphasic and monophasic forms (as well as poorly-
differentiated lesions) share a reproducible tumor-specific chromosome translocation, 
t(X;18)(p11.2;q11.2), which results in the production of one or other of two prinipal 
fusion genes, SYT-SSX1 and SYT-SSX2 (Sanberg et al. 2002). 
2.7 BAF (Brg/Brahama-associated factors) complex and genetic 
mutations 
Studies over the years involving drugs such as histone deacetylase and histone 
methyl transferase inhibitors, hydroxamic acid, sirtuins and others have suggested the 
important role of epigenetic modulation in cancer-indeed, nearly all cancers display 
epigenetic changes, and most cancer mutations, in either a direct or indirect manner, 
affect the epigenome (Dawson et al. 2012). 
Among the most frequent mutations uncovered in human cancer sequencing 
efforts were mutations in genes encoding the subunits of adenosine triphosphate (ATP)-
dependent chromatin remodeling complexes, most notably the mammalian SWI/SNF or 
BAF(Brg/Brahma-associated factors) complexes (Kadoch et al. 2013). Evidence 
indicating that polycomb complexes are an important primary target of mammalian 
SWI/SNF or BAF complexes has emerged in more recent years from the observation 
that mutation of the ATPase Brgl of BAF complexes leads to H3K27Me3 accumulation 
and repression of many genes in embryonic stem (ES) cells (Ho et al. 2011). 
The advent of exome sequencing across a diverse range of human cancers has 
led to the realization that BAF complexes are one of the most significant tumor 
suppressors in humans, with a cumulative incidence of mutation of more than 20 % of 
human cancers sequenced to date (Kadoch et al. 2013). Many cancers (if not most) 
bearing BAF subunit mutations  have a mutation in only one allele of the affected 
subunit, making them dominant tumor suppressors, rather than recessive (Kadoch et al. 
2013). 
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The most commonly affected BAF subunit in cancer is ARID1A (BAF250A) 
which has been found to be mutated in a variety of tumors including endometrial, colon 
and rectal carcinomas (Kandoth et al. 2013). BAF 170 is mutated in gastric and 
colorectal cancers with microsatellite instability. The homologous subunit of BAF155 is 
mutated in about 10% of small cell lung cancers (Kadoch C et al. 2013). 
In certain tumors, specific genes are mutated in 100% of the cancers in 100% of 
the cells, which provides definitive evidence that these mutations cause the development 
and maintenance of the tumor. An example is human synovial sarcoma which has 
provided ground for the discovery of a mechanism underpinning perturbation to the 
SS18 subnuit of BAF complexes by the t(X;18) translocation hallmark to human 
synovial sarcoma (Naka et al. 2010). 
The t(X;18)chromosomal translocation, as illustrated in synovial sarcoma, 
results in the direct fusion of 78 amino acids of C-terminus of SSX to the SS18 terminus 
giving a fusion protein that evicts wild-type SS18 and causes displacement of BAF47. 
The SSX-SS18 containing complexes are then retargeted to oncogenic loci such as 
SOX2 and PAX6, activating these genes by displacement of PRC2 complexes and their 
H3K27me3 repressive marks (Kadoch and Crabtree 2013).  
This oncogenic eviction of polycomb can be reversed by stoichiometrically 
altering the balance of SS18-SSX versus wild-type SS18 within BAF complexes 
thereby reversing the complex to an induced wild-type bearing normal subunit 
composition and hence an exciting therapeutic opportunity emerges from these findings 
(Kadoch and Crabtree 2013). 
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3. AIM OF WORK 
The transcription factor SOX2 was proved to be amplified in different types of 
tumors including small cell lung cancer and many other forms of carcinomas, the aim of 
our study is to examine SOX2 expression in synovial sarcoma and compare the 
expression in this specific soft tissue tumor to other soft tissue tumor entitites including 
fibrosarcoma, rhabdomyosarcoma, liposarcoma and undifferentiated pleomorphic 
sarcoma. 
We are also interested in testing and trying to analyze the Sox2 gene status, in 
positive cases, through further fluorescence in situ hybridization technique.  
Our study also aims to further investigate a SOX2- H3K27me3 relationship if 
present. 
The study attained an approval from the ethics committee of Friedrich-Schiller 
University of Jena, Faculty of medicine; approval number 5318-10/17. 
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5. DISCUSSION 
Soft tissue sarcomas are rare and represent less than 1% of all cancer types. In 
recent years between 3500 and 3750 new cases were registered in Germany each year. 
They can roughly be subdivided into two groups: entities with single, well-characterized 
driver mutations and sarcomas with a complex genotype (Petersen 2017).  
Synovial sarcoma is classified as a soft tissue tumor of uncertain cellular origin 
(Fletcher et al. 2013). It gets its name from its microscopic similarity and proximity to 
the synovium, but in reality the development of tumor cells is not necessarily of 
synovial origin. While it is a soft tissue tumor typically found in the arms or legs and 
usually close to tendon sheaths and joint capsules, it can also occur in other locations, 
such as the heart, brain, and prostate. Synovial Sarcoma accounts for 5%–10% of all 
STS (Spurrell et al. 2005) and 10%–20% of STS in adolescents and young adults 
(Nielsen et al. 2015).  
Although its cellular origin is unclear, Synovial sarcoma (SS) is generally 
divided into two main histological subtypes: monophasic and biphasic. Monophasic SS 
is characterized by the presence of spindle cells and the absence or near-absence of 
glandular epithelial cells, whereas biphasic SS has equal presence of both spindle cells 
and glandular epithelial cells (Spurrell et al. 2005). In addition, monophasic SS displays 
fibrous and sarcomatous cells that are relatively uniform and small and form sheets. In 
contrast, biphasic SS presents with an epithelial appearance. Another characteristic of 
SS is the unique chromosomal translocation (t X;18), which results in fusion of the SYT 
gene to the SSX1, SSX2, or, on rare occasions, the SSX4 gene (Nielsen et al. 2015). 
Recently, major changes took place in the understanding of cancer biology, 
emphasizing the importance of cancer stem cells, and supporting the suggested theory 
that tumors arise from these cells rather than terminally differentiated cells.  
Embryonic cells, whose biology is governed by stem cell transcription factors 
like SOX2, and cancer stem cells, are thought to be closely related. The Embryonic 
stem cells proliferate without apparent limit; they can be propagated clonally and are 
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not subject to contact inhibition or anchorage dependence. These are typical features of 
transformed or tumor cells and this is why embryonic stem cells can be considered as 
conditional tumor cells (Smith 2001). Evidence has recently been accumulating to 
support the hypothesis that solid tumors contain a small population of cancer-stem like 
cells, which exhibit self-renewing capacities and are responsible for tumor maintenance 
and metastases (Visvader and Lindeman 2008). 
The aim of our study was to: 
(1) Examine SOX2 expression in synovial sarcoma. 
Transcription factor SOX2 was proved to be amplified in different types of 
tumors including small cell lung cancer and many forms of squamous cell carcinoma 
(Karachaliou et al. 2013) 
(2) Compare the expression of SOX2 in synovial sarcoma to other soft tissue 
tumors. 
To fulfill this aim, we analzyed tissue microarrays that were prepared in the 
institute of Pathology, Jena University and included a wide variety of soft tissue tumors 
ranging from Fibrosarcoma, Rhabdomyosarcoma, dedifferentiated Liposarcoma, 
undifferentiated pleomorphic sarcoma and many more. 
(3) Analyze mechanisms that may affect SOX2 expression. 
This included an analysis to understand the SOX2 gene status utilizing 
fluorescence in situ hybridization (FISH) technique and studying the H3K27me3 in 
synovial sarcoma.  
Role of SOX2 in synovial sarcoma and other cancer types 
The study was carried out on 60 cases of synovial sarcoma and 343 cases of the 
different other soft tissue tumors that were referred to the Jena consultation and 
reference center of soft tissue tumors. All the tumors were intensively histologically 
studied via at least two soft tissue tumors experts and were further subjected to a wide 
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panel of biomarkers to direct and confirm the histological diagnosis. All the synovial 
sarcoma cases were subjected to FISH to analyze the characteristic t(x;18) translocation. 
The other 343 cases of various soft tissue tumor entities were employed in the 
production of the tissue microarrays. 
Out of the above mentioned 60 synovial sarcomas, 35 (60%) were SOX2 
positive and 25 (40%) were negative. The expression was variable but worth noticing 
was the fact that all the grade 1 tumors were positive while less than 60% of grade 2 and 
grade 3 revealed a positive staining. Similarly, there was a minor difference of SOX2 
positivity in the low proliferative group (56%) versus moderately to highly proliferating 
tumors (63%). This suggests that SOX2 does not seem to be essential for tumor 
progression, but may play a role in the tumor initiation itself (Zayed & Petersen 2018). 
This is also supported by the fact that the majority of the undifferentiated 
sarcomas were SOX2 negative in first place, again hinting that the transcription factor 
Sox2 is probably not essential in the tumor progression phase. 
This was also stated by Abd El-Maqsoud et al. (2014) who identified Sox2 
expression in ductal carcinoma in situ (DCIS) cases with a higher expression rate than 
seen in invasive carcinomas, suggesting a role of Sox2 in the initial stages of breast 
carcinogenesis. In this study, Sox2 expression was significantly associated with comedo 
type, negative hormone receptor status, and the triple-negative phenotype. However a 
positive association of Sox2 expression with high-grade DCIS was not reached. 
The relationship between SOX2 expression and tumor behavior is highly 
controversial. The fact that some studies reported even better tumor behavior with 
SOX2 expression is to be highlighted. For example, in a study conducted by Züllig and 
colleagues, they managed to investigate and analyze the process of early lymphatic 
metastasisis in squamous cell carcinoma of the oral cavity and demonstrated a 
significant association between cancer cells that strongly expressed SOX2 and a lower 
risk of lymph node metastases. Lu, (2010) and colleagues also reported that patients 
with squamous tumors with expression of SOX2 mRNA above the median enjoyed a 
better prognosis than those with lower levels of expression.  
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This is also consistent with Wilbertz and colleagues who reported in squamous 
cell lung carcinoma that their data clearly demonstrate an association between elevated 
SOX2 expression and indicators of better patient outcome, most importantly prolonged 
overall survival. Furthermore, increased levels of SOX2 amplification indicate a better 
histological differentiation grade and a trend to improved patient survival.  
Consistently, Bass et al.‘s (2009)  findings, indicated that patients with lung 
squamous cell carcinomas harboring an embryonic stem cell-like gene expression 
signature, including SOX2 expression, exhibited significant better survival than patients 
with tumors lacking this signature. 
On the contrary, Neumann et al. demonstrated that increased expression of either 
SOX2 or nuclear β-catenin was associated with distant metastasis in right-sided colon 
cancer. Additionally, SOX2 was also associated with lymph-node metastases. 
According to them, this data underlined the importance of stemness-associated markers 
for the identification of colon cancer with a high risk for distant spread. 
According to Russo et al., SOX2 overexpression upregulated pluripotency and 
epithelial-mesenchymal transition (EMT) transcription factors, along with growth, 
angiogenic and lymphangiogenic factors, and promoted prostate cancer cell 
invasiveness. 
In our study, SOX2 reactivity did also not correlate with higher tumor grades. 
There was also no detectable relation with tumor proliferative activity which was 
assessed by Ki67 immunostaining. 
SOX2 amplification 
Sox2 amplification is characteristic for squamous cell carcinoma (SCC) 
pathogenesis and this can be correlated with the fact that lung SCC, similar to SCC 
from other organs, typically has a 3q overrepresentation/amplification. In contrast, 
adenocarcinomas of the lung harbor much less SOX2 amplifications (Karachaliou 
2013). It should also be noted that alterations of chromosome 3, in particular 3p 
deletions being frequently associated with 3q gains, are considered early events in head 
and neck as well as lung carcinogenesis (Bockmühl et al. 1996 ; Petersen et al. 1997). 
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Interestingly, it has been shown that SOX2 and PIK3CA, both located at 3q26-
q28 and generally coamplified in lung SCC; cooperate in the transition of lung 
dysplasia into cancer (Kim et al. 2016). 
It was also reported that SOX2 regulates cell cycle-related genes positively or 
negatively. CDKN1A, which induces G1 arrest, is repressed by SOX2 in lung 
carcinoma cells, pancreatic cancer cells (Chen et al., 2012) and gastric cancer cells 
(Otsubo et al. 2008). CDKN1B, which also induces G1 arrest, is repressed by SOX2 in 
pancreatic cancer cells and gastric cancer cells. CCND1, which accelerates the cell 
cycle, is activated by SOX2 in gastric cancer cells and MCF7 breast cancer cells (Chen 
et al. 2008) SOX2 represses cell cycle inhibitors and activates cell cycle accelerators; 
however, the pattern of gene regulation is not universal in different cancer cell types. 
In squamous cell lung carcinoma, SOX2 amplifications were reported in 27% of 
cases being correlated with SOX2 expression. Inhibition of SOX2 protein expression by 
transfection of short hairpin RNA in SCLC cell lines with SOX2 expression resulted in 
reduced cell proliferation. In addition, it was mentioned that induction of SOX2 in lung 
epithelial cells increased the number of neural progenitor cells (Rudin et al. 2012). 
According to a study carried out by Gut et al. (2018) based on 55 squamous cell 
carcinomas of the vulva, SOX2 amplification was found in 20.8%; 27.3% of vulvar 
carcinomas showed SOX2 protein overexpression. SOX2 amplification was correlated 
with SOX2 overexpression in their data set (P<0.01). Amplification of the SOX2 locus 
was associated with high tumor grade (P<0.05) and human papillomavirus (HPV) 
positivity (P<0.01). SOX2-amplified tumors showed more frequently a basaloid 
phenotype than nonamplified carcinomas. SOX2 protein overexpression was also 
correlated with basaloid phenotype and positive HPV status of vulvar carcinomas. 
SOX2 regulation and its interplay with SSX-SS18, H3K27me3 and signaling 
pathways 
In squamous lung and esophageal cancers, aberrant SOX2 expression was linked 
to the genomic amplification of its chromosomal location on chromosome 3q26.33. 
Chromosome 3q copy number gains are a common event in breast cancers and have 
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been implicated as an independent predictor of poor prognosis in node-negative breast 
cancers (Janssen et al. 2003) 
Therefore some of the positive SOX2 synovial sarcoma cases were further 
subjected to a molecular study via FISH to detect amplification on the genetic level, but 
all were negative. None of the positive cases revealed an amplification, thus gene copy 
number alterations do not seem to play a role in SOX2 upregulation in this tumor entity 
(Zayed and Petersen 2018).  
Our results were consistent with Lengerke and colleagues (2011) who analyzed 
lymph node metastases of breast cancer to explore whether aberrant SOX2 expression is 
a result of gene amplification as reported in other carcinomas. With the exception of one 
case of low level amplification in a score 3 primary tumor, the majority of analyzed 
samples did not show SOX2 gene amplifications, suggesting that at least in breast 
carcinomas expressing SOX2, the aberrant gene expression is mostly driven by other 
mechanisms. 
Different studies were conducted in attempt to understand the SOX2 
overexpression mechanism and associated genetic alterations. In 2013, the interplay 
between SS18-SSX fusion, histone modification and SOX2 expression was highlighted 
by Kadoch and Crabtree (2013). They reported that the SS18-SSX fusion protein of 
synovial sarcoma leads to alterations in the human SWI/SNF chromatin remodeling 
complex. Similar to SS18, the fusion protein incorporates into the SWI/SNF complex 
resulting in the exclusion of the tumor suppressor gene BAF47 (also known as INI1 and 
SMARCB1), another component of the complex, resulting in its inactivation. The 
SWI/SNF complex antagonizes the activity of the Polycomb repressive complex 2 
(PRC2) being responsible for trimethylation of lysine 27 of histone H3 (HeK27me3) by 
the methyltransferase EZH2 forming an essential component of the PRC2 complex and 
being considered a repressive mark for gene transcription (Kadoch et al. 2016). This 
was actually the reason why we considered analyzing global HeK27me3 expression in 
our synovial sarcoma cases.  
The statistical analysis revealed a high statistically significant correlation 
between SOX2 and H3K27me3 expression (p<0.0005, Chi square test). Out of 35 
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SOX2 positive synovial sarcoma cases, 25 (71, 4%) were HeK27me3 positive and 10 
(28, 6%) were negative (Zayed and Petersen 2018). Kadoch and Crabtree also reported 
that the altered SWI/SNF complex in synovial sarcoma binds to SOX2 gene locus 
resulting in SOX2 activation by a local decrease in H3K27me3.  This situation may be 
similar to seminoma in which a repressive H3K27me3 mark at the SOX2 locus is 
responsible for SOX2 repression while there seems to be H3K27me3 expression at least 
in a subset of neoplasms of this entity (Kushwaha et al. 2016; Kristensen et al. 2012). 
Surface and colleagues (2010) reported that methylation of Histone H3 at the 
lysine 27 residue is mediated by the histone methyltransferase EZH2. Enhancer of zeste 
homologue 2 (EZH2) showed high expression in cells possessing embryonic gene 
expression signature, while its amount declines with tissue maturation and 
differentiation. Abnormal overexpression of EZH2 has been reported in a wide variety 
of tumor types including carcinomas, lymphomas, cutaneous melanoma, and soft tissue 
sarcomas (Chang and Hung 2012). 
Kimura and colleagues (2016) also explored specific markers and discovered 
that synovial sarcoma cell lines possessed heterogeneity by way of containing a sphere-
forming subpopulation highly expressing Nanog, Oct4 and SOX2. By expression 
microarray analysis, CXCR4 was identified to be highly expressed in the sphere 
subpopulation and correlated with stem-cell associated markers. According to their 
study, stem-cell associated markers including SOX2 and SS18/SSX were highly 
expressed in the sphere/forming population of synovial sarcoma, hence SS18/SSX and 
its sphere-specific binding proteins might regulate tumor-initiating cells via epigenetic 
and/or transcriptional deregulation. 
Generally, the impact of H3K27me27 expression on cancer prognosis seems to 
be complex as there are also many studies reporting a better outcome in tumors with 
high expression, e.g. in colorectal and breast cancer (Bae et al. 2014; Benard et al. 
2014). 
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Tumor progression of synovial sarcoma 
In synovial sarcoma, endogenous EZH2 expression correlated with H3K27me3 
at PcG target genes. It has been reported that high expression of EZH2 and H3K27me3 
helps to distinguish poorly differentiated synovial sarcoma from monophasic and 
biphasic subtypes and is associated with unfavorable clinical outcome (Changchien et 
al. 2012). However our study does not provide such evidence, but it is important to 
mention the limitation of our tumor collective lacking data on metastatic spread and 
survival.  
Metastasis and tumor progression in synovial sarcoma seem to be driven not 
only by epigenetic modifications like histone methylation but also additional 
chromosomal changes apart from the defining t(X;18)(p11.2;q11.2) translocation and 
the activation of other genes and pathways distinct from the SS18-SSX gene fusion 
event (de Necochea-Campion et al. 2017). The CINSARC signature of 67 genes 
correlating with chromosomal instability and prognosis in undifferentiated sarcoma was 
also highly significant in stratifying synovial sarcoma with respect to metastatic 
outcome (Lagarde et al. 2013).  
Future sarcoma diagnostics 
Recent studies assure the inevitable importance of understanding tumors’ 
specific genetic mutations and utilizing this aspect in diagnostic measures as well as 
future elaborated gene based therapeutic regimes. For example in our study we clearly 
demonstrated the importance of the SS18-SSX gene fusion and its downstream targets 
SOX2 and H3K27me3 in synovial sarcoma. The entity provides a paradigm of a tumor 
that is primarily driven by alterations in the epigenome. The strength of the SS18-SSX 
alteration lies in the fact that the fusion gene has influence on two major players in 
epigenetic regulation. This leads to the inactivation of tumor suppressive functions of 
the SWI/SNF nucleosome remodeling complex and changes Histone chromatin marks 
that leads to the activation of the cancer stem cell transcription factor SOX2 as well as 
other genes that are normally suppressed by the polycomb repressive complexes 1 and 2 
(Banito et al. 2018). 
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In a study conducted by Koelsche and colleagues (2018) they stated that 
undifferentiated solid tumors with small blue round cell histology and expression of 
CD99 mostly resemble Ewing sarcoma; however, this group of smal round cell tumors 
may also include other tumors such as mesenchymal chondrosarcoma, synovial 
sarcoma, or small cell osteosarcoma. They assured that definitive classification usually 
requires detection of entity-specific mutations. Hence they generated genome-wide 
DNA-methylation profiles of 30 small blue round cell tumors not otherwise specified: 
14  (47%) assigned to Ewing sarcoma, 6 (20%) to small blue round cell tumors with 
CIC alteration, 4 (13%) to small blue round cell tumors with BCOR alteration, which is 
a methylation group composed of small blue round cell  tumors with BCOR–CCNB3 
fusion and clear cell sarcoma of the kidney with BCOR internal tandem duplication, 
two (7%) to synovial sarcomas, two (7%) to malignant rhabdoid tumors, and one (3%) 
to mesenchymal chondrosarcomas.They also assured that genetic analyses validated the 
predicted sarcoma subtypes in most cases. 
It is important to note that synovial sarcoma is characterized by a recurrent 
pattern of DNA methylation that can be used to separate and diagnose this entity against 
50 other soft tissue tumor types using genome-wide methylation analysis and 
bioinformatical classification algorithms. The methylome analysis provides in addition 
a global gene copy profile which may help to establish prognostic subgroups of this 
entity (Petersen 2017; Köelsche et al. 2015). 
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6. CONCLUSION 
 
Our study proved a significant SOX2-expression in about 60% of the 60 
synovial sarcoma cases investigated, whereas other soft tissue tumor entities showed 
very sporadic insignificant expression in only 13 out of 343 variable tumors.  
Alongside our findings support other studies reporting SOX2 and H3K27me3 
expression in synovial sarcoma which reveals that both biomarkers are related to each 
other.  
This fact strengthens the notion that the tumor type is driven by epigenetic 
processes similar to those that are operating in pluripotent stem cells. The relevance of 
these parameters in the pathway pathology of synovial sarcoma, i.e. the timing and 
dosing of SOX2 and H3K27me3 expression initiated by the SS18-SSX driver mutation 
together with the interplay of these events with other signaling pathways, cellular 
mechanisms and additional mutations in tumor progression, will require further studies. 
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